Novel Diabetes Drugs and the Cardiovascular Specialist.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2017.04.014
Abstract: Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce events in patients with diabetes and cardiovascular (CV) disease, a group common in cardiology clinics. The sodium-glucose cotransporter 2 inhibitor,… read more here.
Keywords: cardiology; novel diabetes; diabetes drugs; drugs cardiovascular ... See more keywords
POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32463-3
Abstract: Novel diabetes agents (glucagon-like-peptide-1 receptor agonists, GLP-1 RA and sodium-glucose cotransport-2 inhibitors, SGLT2i) reduced death and cardiovascular events in randomized trials, but uptake in clinical practice has lagged. We assessed the unrealized potential for reduction… read more here.
Keywords: potential unrealized; diabetes agents; unrealized cardiovascular; novel diabetes ... See more keywords
Retracted: A Novel Diabetes Healthcare Disease Prediction Framework Using Machine Learning Techniques
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Healthcare Engineering"
DOI: 10.1155/2023/9872970
Abstract: [This retracts the article DOI: 10.1155/2022/1684017.]. read more here.
Keywords: disease prediction; novel diabetes; diabetes healthcare; prediction framework ... See more keywords